Prognostic Factors and Recurrence in Breast Cancer: Experience at the National Cancer Institute of Mexico

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Hormonal treatment</td><td align="center">Recurrence group</td><td align="center">Control group</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">No</td><td align="center">32 (53.33%)</td><td align="center">27 (45.00%)</td></tr><tr><td align="left">Tamoxifen</td><td align="center">26 (43.33%)</td><td align="center">27 (45.00%)</td></tr><tr><td align="left">Aromatase Inhibitors</td><td align="center">2 (3.33%)</td><td align="center">6 (10.00%)</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Patients with positive hormone receptors who were treated with adjuvant hormone therapy for five years.

International Scholarly Research Notices

tab4

Table 4

Table 4: Prognostic Factors and Recurrence in Breast Cancer: Experience at the National Cancer Institute of Mexico 